Methylphenidate extended-release chewable tablets - Pfizer

Drug Profile

Methylphenidate extended-release chewable tablets - Pfizer

Alternative Names: NWP-09; QuilliChew ER

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NextWave Pharmaceuticals
  • Developer Pfizer; Tris Pharma
  • Class Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 24 May 2018 Pfizer plans a phase IV trial for Attention-deficit hyperactivity disorder (In children 4-5 years) in June 2018 (NCT03536390)
  • 07 Dec 2015 Registered for Attention-deficit hyperactivity disorder (In children 6 years and above)- First global approval in USA (PO)
  • 07 Dec 2015 Adverse events data from the REFOCUS phase III trial in Attention-deficit hyperactivity disorder released by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top